MedQuist Holdings Adds Development Leader
28 Novembre 2011 - 12:45PM
MedQuist Holdings Inc. (Nasdaq:MEDH), a leading provider of
integrated clinical documentation solutions for the U.S. healthcare
system, announced today the continued enhancement of the company's
senior management team with the addition of Matt Jenkins as the
Senior Vice President of Corporate Business Development.
In his new role, Mr. Jenkins will be responsible for leading the
company's development of strategic partnerships, including all
aspects of inorganic growth such as acquisitions, investments and
alliances. He brings a deep understanding of the healthcare
information technology industry to MedQuist and a proven track
record in successfully executing key transactions, relationships
and developing high-growth strategies.
"Our development of an ecosystem of partners is helping us
quickly expand our market access through an increased value
proposition to customers and validates the strength of our
cloud-based, context-enabled speech and natural language
understanding technologies," said Vern Davenport, Chairman and
Chief Executive Officer for MedQuist Holdings. "Matt's experience
and associations within the industry will be instrumental in
accelerating the execution of this strategy as we move into 2012
and beyond. He's an excellent addition to our senior leadership
team."
Mr. Jenkins formerly led corporate development at Allscripts
where he helped transform Allscripts through a period of dynamic
growth, including the merger with Eclipsys in 2010, the 2008 merger
with Misys Healthcare, the divesture of the Misys Hospital
businesses in 2007 and several other transactions. As Vice
President of Corporate Development and member of the Misys
Healthcare operating board (Misys, plc) his responsibilities
included developing the strategic plan for the portfolio and
leading the formation of many partnerships and alliances. Mr.
Jenkins has also held operational leadership roles in the
ambulatory, acute, and post-acute business lines of
Allscripts.
Prior to Allscripts, Mr. Jenkins was one of the three founding
members of Cellective Therapeutics (acquired by AstraZeneca), a
venture-funded biotechnology firm focused on developing
industry-leading therapeutic antibodies for the treatment of
oncology and immune-related diseases. His background also includes
roles in the venture capital and consulting fields. Mr. Jenkins
holds a Bachelor of Science in Business Administration and his MBA
from University of North Carolina at Chapel Hill.
About MedQuist
MedQuist is a leading provider of clinical narrative capture
services, Speech Understanding technology from M*Modal and clinical
documentation workflow. MedQuist's enterprise solutions – including
mobile voice capture devices, speech recognition, Web-based
workflow platforms and global network of medical editors – help
healthcare facilities facilitate adoption of electronic health
records (EHR), improve patient care, increase physician
satisfaction and lower operational costs. For more information,
please visit www.medquist.com.
"Safe Harbor" Statement under the U.S. Private Securities
Litigation Reform Act of 1995: Statements in this press release
regarding MedQuist's business that are not historical facts are
"forward-looking statements" that involve risks and uncertainties.
Actual outcomes and results may differ materially from what is
expressed or forecasted in forward-looking statements. As a result,
forward-looking statements speak only as of the date they were
made, and the Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Photo available at
http://ir.medquistholdings.com/index.php?s=142&item=72
CONTACT: Investor Contacts:
Ron Scarboro
Chief Financial Officer
ronald.scarboro@medquist.com
(615) 798-4350
Tripp Sullivan
Corporate Communications, Inc.
tripp.sullivan@cci-ir.com
(615) 324-7335
Media Contact:
Thomas Mitchell
Director of Marketing
tmitchell@medquist.com
(615) 798-6630
Grafico Azioni Medx (PK) (USOTC:MEDH)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Medx (PK) (USOTC:MEDH)
Storico
Da Gen 2024 a Gen 2025